NBIX SEC-Einreichungen - Neurocrine Biosciences, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

LEI	549300FECER0XBN49756
CIK	914475

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Neurocrine Biosciences, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 28, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 NEUROCRINE BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
May 18, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 NEUROCRINE BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commission
May 18, 2026	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001
May 18, 2026	EX-99.(A)(5)(H)	Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics EX-99.(a)(5)(H) Exhibit (a)(5)(H) Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics • Strengthens Neurocrine’s rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome • Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 – Neurocrine Biosciences, Inc. (N
May 18, 2026	EX-10.1	CREDIT AGREEMENT dated as of May 14, 2026 NEUROCRINE BIOSCIENCES, INC., as Borrower, The Lenders Party Hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent, JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., CITIBANK, N.A., GOLDMAN SACHS BANK US EX-10.1 Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of May 14, 2026 among NEUROCRINE BIOSCIENCES, INC., as Borrower, The Lenders Party Hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent, JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., CITIBANK, N.A., GOLDMAN SACHS BANK USA and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Joint Lead Arrangers, Joint Bookrunners and Co-Syndicati
May 18, 2026	EX-99.1	Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics EX-99.1 Exhibit 99.1 Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics • Strengthens Neurocrine’s rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome • Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX)
May 18, 2026	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001
May 18, 2026	EX-99.(A)(5)(H)	Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics EX-99.(a)(5)(H) Exhibit (a)(5)(H) Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics • Strengthens Neurocrine’s rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome • Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 – Neurocrine Biosciences, Inc. (N
May 5, 2026	EX-99.1	Neurocrine Biosciences Reports First-Quarter 2026 Financial Results Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (d Exhibit 99.1 Neurocrine Biosciences Reports First-Quarter 2026 Financial Results Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study
May 5, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-22705 NEUROCRINE
May 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 NEUROCRINE BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number
April 29, 2026	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001
April 29, 2026	EX-99.(A)(5)(G)	Dear Soleno Therapeutics Employees, EX-99.(a)(5)(G) Exhibit (a)(5)(G) Dear Soleno Therapeutics Employees, This is an important moment for both organizations, and we recognize that it may bring questions and some uncertainty. We are committed to supporting you through this transition with clear, timely communication and as much transparency as possible. This transaction reflects the strength of your work and the shared opportunity ah
April 29, 2026	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001
April 29, 2026	EX-99.(A)(5)(G)	Dear Soleno Therapeutics Employees, EX-99.(a)(5)(G) Exhibit (a)(5)(G) Dear Soleno Therapeutics Employees, This is an important moment for both organizations, and we recognize that it may bring questions and some uncertainty. We are committed to supporting you through this transition with clear, timely communication and as much transparency as possible. This transaction reflects the strength of your work and the shared opportunity ah
April 28, 2026	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001
April 28, 2026	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001
April 20, 2026	EX-FILING FEES	Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 2,882,219,157.
April 20, 2026	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per share (Title of
April 20, 2026	EX-99.(A)(1)(C)	Offer To Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. a Delaware corporation $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 SIGMA MERGER SUB, INC. a direct wholly owned subsidiary EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer To Purchase All Outstanding Shares of Common Stock of SOLENO THERAPEUTICS, INC. a Delaware corporation at $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE ONE MINUTE FOLLOWING 11:59 P.M
April 20, 2026	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC. (Name of Subject Company) SIGMA MERGER SUB, INC. (Offeror) NEUROCRINE BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per share (Title of
April 20, 2026	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL to Tender Shares of Common Stock of SOLENO THERAPEUTICS, INC., at $53.00 per share, payable in cash pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC., a direct wholly owned subsidiary of NEUROCRINE EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of SOLENO THERAPEUTICS, INC., at $53.00 per share, payable in cash pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC., a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. The undersigned represents that I (we) have full authority to surrender without restriction the c
April 20, 2026	EX-99.(A)(1)(C)	Offer To Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. a Delaware corporation $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 SIGMA MERGER SUB, INC. a direct wholly owned subsidiary EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer To Purchase All Outstanding Shares of Common Stock of SOLENO THERAPEUTICS, INC. a Delaware corporation at $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE ONE MINUTE FOLLOWING 11:59 P.M
April 20, 2026	EX-99.(A)(1)(D)	Offer To Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. a Delaware corporation $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 SIGMA MERGER SUB, INC. a direct wholly owned subsidiary EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer To Purchase All Outstanding Shares of Common Stock of SOLENO THERAPEUTICS, INC. a Delaware corporation at $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE ONE MINUTE FOLLOWING 11:59 P.M
April 20, 2026	EX-99.(A)(1)(A)	Offer to Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. $53.00 per share, payable in cash SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE ONE MI EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of SOLENO THERAPEUTICS, INC. at $53.00 per share, payable in cash by SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE ONE MINUTE FOLLOWING 11:59 P.M. EASTERN TIME ON MAY 15, 2026, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.
April 20, 2026	EX-99.(D)(3)	Confidentiality Agreement EX-99.(D)(3) Exhibit (d)(3) Soleno Confidential Soleno Therapeutics, Inc. 100 Marine Parkway Suite 400 Redwood City, CA 94065 650-213-8444 Main CONFIDENTIAL Neurocrine Biosciences, Inc. 6027 Edgewood Bend Court San Diego, CA 92130 Confidentiality Agreement Ladies and Gentlemen: In connection with your consideration of a potential negotiated acquisition or negotiated business combination transa
April 20, 2026	EX-FILING FEES	Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 2,882,219,157.
April 20, 2026	EX-99.(A)(1)(D)	Offer To Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. a Delaware corporation $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 SIGMA MERGER SUB, INC. a direct wholly owned subsidiary EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer To Purchase All Outstanding Shares of Common Stock of SOLENO THERAPEUTICS, INC. a Delaware corporation at $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE ONE MINUTE FOLLOWING 11:59 P.M
April 20, 2026	EX-99.(D)(3)	Confidentiality Agreement EX-99.(D)(3) Exhibit (d)(3) Soleno Confidential Soleno Therapeutics, Inc. 100 Marine Parkway Suite 400 Redwood City, CA 94065 650-213-8444 Main CONFIDENTIAL Neurocrine Biosciences, Inc. 6027 Edgewood Bend Court San Diego, CA 92130 Confidentiality Agreement Ladies and Gentlemen: In connection with your consideration of a potential negotiated acquisition or negotiated business combination transa
April 20, 2026	EX-99.(A)(1)(E)	Notice of Offer to Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. a Delaware corporation $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 SIGMA MERGER SUB, INC. a direct wholly owned EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely pursuant to the Offer to Purchase, dated April 20, 2026, and the related Letter of Transmittal (as defined below) and
April 20, 2026	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL to Tender Shares of Common Stock of SOLENO THERAPEUTICS, INC., at $53.00 per share, payable in cash pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC., a direct wholly owned subsidiary of NEUROCRINE EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of SOLENO THERAPEUTICS, INC., at $53.00 per share, payable in cash pursuant to the Offer to Purchase dated April 20, 2026 by SIGMA MERGER SUB, INC., a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. The undersigned represents that I (we) have full authority to surrender without restriction the c
April 20, 2026	EX-99.(A)(1)(E)	Notice of Offer to Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. a Delaware corporation $53.00 per share, payable in cash Pursuant to the Offer to Purchase dated April 20, 2026 SIGMA MERGER SUB, INC. a direct wholly owned EX-99.(a)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely pursuant to the Offer to Purchase, dated April 20, 2026, and the related Letter of Transmittal (as defined below) and
April 20, 2026	EX-99.(A)(1)(A)	Offer to Purchase All Outstanding Shares of Common Stock SOLENO THERAPEUTICS, INC. $53.00 per share, payable in cash SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE ONE MI EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of SOLENO THERAPEUTICS, INC. at $53.00 per share, payable in cash by SIGMA MERGER SUB, INC. a direct wholly owned subsidiary of NEUROCRINE BIOSCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE ONE MINUTE FOLLOWING 11:59 P.M. EASTERN TIME ON MAY 15, 2026, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED.
April 15, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 15, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 15, 2026	ARS	ARS Annual Report 2025RESEARCH & DEVELOPMENT Therapeutic Area Diversification: NEUROLOGY PSYCHIATRY ENDOCRINOLOGY IMMUNOLOGY Psychiatry pipeline to deliver multiple first- and best-in-class medicines this decade Redesigned R&D organization delivering diverse, high-quality candidates, enabling repeatable value creation opportunities CRF-based therapies offer third growth horizon in endocrinology and me
April 7, 2026	EX-99.(A)(5)(F)	Corrected Transcript EX-99.(a)(5)(F) Exhibit (a)(5)(F) Corrected Transcript 06-Apr-2026 Neurocrine Biosciences, Inc. (NBIX) Acquisition of Soleno Therapeutics by Neurocrine Call 1-877-FACTSET www.callstreet.com Total Pages: 14 Copyright © 2001-2026 FactSet CallStreet, LLC Neurocrine Biosciences, Inc. (NBIX) Acquisition of Soleno Therapeutics by Neurocrine Call Corrected Transcript 06-Apr-2026 CORPORATE PARTICIPANTS To
April 7, 2026	EX-99.(A)(5)(F)	Corrected Transcript EX-99.(a)(5)(F) Exhibit (a)(5)(F) Corrected Transcript 06-Apr-2026 Neurocrine Biosciences, Inc. (NBIX) Acquisition of Soleno Therapeutics by Neurocrine Call 1-877-FACTSET www.callstreet.com Total Pages: 14 Copyright © 2001-2026 FactSet CallStreet, LLC Neurocrine Biosciences, Inc. (NBIX) Acquisition of Soleno Therapeutics by Neurocrine Call Corrected Transcript 06-Apr-2026 CORPORATE PARTICIPANTS To
April 7, 2026	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Me SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Merger Sub, Inc. (Offeror) a wholly owned subsidiary of Neurocrine Biosciences, Inc. (Parent of Offeror) Common Stock, $0.001 Par Value (Title o
April 7, 2026	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Me SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Merger Sub, Inc. (Offeror) a wholly owned subsidiary of Neurocrine Biosciences, Inc. (Parent of Offeror) Common Stock, $0.001 Par Value (Title o
April 6, 2026	EX-99.1	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio VYKATTM XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative The EX-99.1 Exhibit 99.1 Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio VYKATTM XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine’s High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) an
April 6, 2026	EX-99.(A)(5)(E)	1 EX-99.(a)(5)(E) Exhibit (a)(5)(E) NBIX – IR FAQ BUSINESS / DEAL 1. Why is Neurocrine acquiring Soleno Therapeutics and why now? a. VYKAT XR is a first-in-class medicine, consistent with INGREZZA and CRENESSITY, and aligned with our commitment to innovative medicines for patients with high unmet need b. Neurocrine is acquiring a de-risked commercial asset with strong early validation c. VYKAT XR si
April 6, 2026	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Me SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Merger Sub, Inc. (Offeror) a wholly owned subsidiary of Neurocrine Biosciences, Inc. (Parent of Offeror) Common Stock, $0.001 Par Value (Title o
April 6, 2026	EX-99.(A)(5)(C)	Hi everyone, EX-99.(a)(5)(C) Exhibit (a)(5)(C) Hi everyone, This morning, we announced the exciting news that Neurocrine has entered into a definitive agreement to acquire Soleno Therapeutics , a commercial-stage biopharmaceutical company with an FDA-approved rare endocrinology product on the market that treats hyperphagia, the defining feature of Prader-Willi syndrome (PWS). Since the start of this year, you’
April 6, 2026	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Me SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Soleno Therapeutics, Inc. (Name of Subject Company (Issuer)) Sigma Merger Sub, Inc. (Offeror) a wholly owned subsidiary of Neurocrine Biosciences, Inc. (Parent of Offeror) Common Stock, $0.001 Par Value (Title o
April 6, 2026	EX-99.(A)(5)(D)	Dear Soleno Colleagues, EX-99.(a)(5)(D) Exhibit (a)(5)(D) Dear Soleno Colleagues, As you have undoubtedly already heard, this morning Neurocrine and Soleno Therapeutics entered into a definitive agreement for Neurocrine to acquire Soleno. This marks an important milestone for both companies in our collective journey to deliver life-changing treatments for patients with great needs. First and foremost, thank you for your
April 6, 2026	EX-99.(A)(5)(E)	1 EX-99.(a)(5)(E) Exhibit (a)(5)(E) NBIX – IR FAQ BUSINESS / DEAL 1. Why is Neurocrine acquiring Soleno Therapeutics and why now? a. VYKAT XR is a first-in-class medicine, consistent with INGREZZA and CRENESSITY, and aligned with our commitment to innovative medicines for patients with high unmet need b. Neurocrine is acquiring a de-risked commercial asset with strong early validation c. VYKAT XR si
April 6, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2026 NEUROCRINE BIOSCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2026 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commissio
April 6, 2026	EX-99.2	Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of each of Soleno and Neurocrine, including statements relating to the ability EX-99.2 Neurocrine Biosciences to Acquire Soleno Therapeutics April 6, 2026 Exhibit 99.2 Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of each of Soleno and Neurocrine, including statements relating to the ability to complete and the timing of completion of the transactions
April 6, 2026	EX-10.1	TENDER AND SUPPORT AGREEMENT EX-10.1 Exhibit 10.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), is made and entered into as of April 5, 2026, by and among Neurocrine Biosciences Inc., a Delaware corporation (“Parent”), Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the undersigned holders (each, a “Holder” and collectively, the “Ho
April 6, 2026	EX-99.(A)(5)(D)	Dear Soleno Colleagues, EX-99.(a)(5)(D) Exhibit (a)(5)(D) Dear Soleno Colleagues, As you have undoubtedly already heard, this morning Neurocrine and Soleno Therapeutics entered into a definitive agreement for Neurocrine to acquire Soleno. This marks an important milestone for both companies in our collective journey to deliver life-changing treatments for patients with great needs. First and foremost, thank you for your
April 6, 2026	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2026 NEUROCRINE BIOSCIEN SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2026 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (C
April 6, 2026	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among NEUROCRINE BIOSCIENCES, INC., SIGMA MERGER SUB, INC. SOLENO THERAPEUTICS, INC. Dated as of April 5, 2026 EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among NEUROCRINE BIOSCIENCES, INC., SIGMA MERGER SUB, INC. and SOLENO THERAPEUTICS, INC. Dated as of April 5, 2026 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Certain Interpretations 18 ARTICLE II THE OFFER 20 2.1 The Offer 20 2.2 Company Actions 22 ARTICLE III THE MERGER 23 3.1 Merger of P
April 6, 2026	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2026 NEUROCRINE BIOSCIEN SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2026 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (C
April 6, 2026	EX-99.(A)(5)(C)	Hi everyone, EX-99.(a)(5)(C) Exhibit (a)(5)(C) Hi everyone, This morning, we announced the exciting news that Neurocrine has entered into a definitive agreement to acquire Soleno Therapeutics , a commercial-stage biopharmaceutical company with an FDA-approved rare endocrinology product on the market that treats hyperphagia, the defining feature of Prader-Willi syndrome (PWS). Since the start of this year, you’
November 24, 2025	EX-10.1	Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amendment to Amended and Restated Employment Agreement (this “Amendment”), is made as of November 21, 2025, by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court exhibit101 Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amendment to Amended and Restated Employment Agreement (this “Amendment”), is made as of November 21, 2025, by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”), and Eiry W. Roberts, M.D. (hereinafter “Employee”). Capitalized terms used but n
November 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2025 NEUROCRINE BIOS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
October 28, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCR
October 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 NEUROCRINE BIOSC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N
October 28, 2025	EX-99.1	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2025 Financial Results Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth CRENESSITY® (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with 540 Total New Patient Enrollmen
July 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B
July 30, 2025	EX-99.1	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 202 Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2025 Financial Results Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 NEUROCRINE BIOSCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Numb
May 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 NEUROCRINE BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
May 30, 2025	EX-10.1	Amended and Restated Employment Agreement dated May 30, 2025 between the Company and Eiry W. Roberts, M.D. exhibit101 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into as of May 30, 2025 and made effective as of the Effective Date (defined in Annex I) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I
May 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 NEUROCRINE BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
May 21, 2025	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables S-8 NEUROCRINE BIOSCIENCES INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.
May 21, 2025	S-8	As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	EX-99.6	Form of Director Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.6 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN RSU AWARD GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The RSU Award is subject to all of
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	EX-99.5	Form of Director Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.5 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set
May 21, 2025	EX-99.1	Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended and restated Exhibit 99.1 NEUROCRINE BIOSCIENCES, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 6, 2018 APPROVED BY THE STOCKHOLDERS: MAY 24, 2018 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2025 APPROVED BY THE STOCKHOLDERS: MAY 21, 2025 1. GENERA
May 21, 2025	EX-99.2	Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.2 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 14, 2025 APPROVED BY THE STOCKHOLDERS: MAY 21, 2025 1. GENERAL. (a) Relationship to Prior Plans. The Plan is the successor to the 2020 Plan. As of the Effective Date: (i) no additional awards may be granted under the 2020 Plan; and (ii) all Prior Plan Awards will remain subject to the
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	EX-99.4	Form of Standard Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.4 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN RSU AWARD GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The RSU Award is subject to all of
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	EX-99.8	Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.8 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN RSU AWARD GRANT NOTICE – NON-U.S. Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The RSU Award is subjec
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	EX-99.3	Form of Standard Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.3 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set
May 21, 2025	EX-99.7	Form of Non-U.S. Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan Exhibit 99.7 NEUROCRINE BIOSCIENCES, INC. 2025 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE – NON-U.S. Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and cond
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 21, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 21, 2025 S-8 POS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.
May 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 NEUROCRINE BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number
May 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE
May 5, 2025	EX-99.1	Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billio Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiat
May 5, 2025	EX-10.8	between Takeda Pharmaceutical Company Limited and the Company Exhibit 10.8 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. CONFIDENTIAL Execution Version AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND NEUROCRINE BIOSCIENCES
May 5, 2025	EX-10.1	Form of Stock Option Grant Notice and Option Agreement for grants made Exhibit 10.1 NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN OPTION GRANT NOTICE Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set
April 9, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 9, 2025	ARS	ARS Annual Report 2024Discovered and Developed Four Novel FDA- Approved Programs Deep Expertise in Neuroscience Drug Development Fully-Integrated Organization with R&D and Commercial Capabilities Growing Blockbuster Commercial Product in INGREZZA with Strong IP Future Blockbuster Opportunity with CRENESSITY Industry-Leading Portfolio of Muscarinic Compounds NEUROCRINE DISCOVERED / DEVELOPED Our Pipeline Today – 12 Programs Phase 1 Phase 2 Phase 3 NEUROLOGY valbenazine (VMAT2 Inhibitor) Dyskinetic Cerebral Palsy NBI-’986 (M4 Antagonist) Movement Disorders NBI-’355 (Nav1.
April 9, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 4, 2025	EX-99.1	Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer Exhibit 99.1 Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer • Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company’s executive managem
April 4, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
February 10, 2025	EX-21.1	Subsidiaries of the Company Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine International, Inc. Delaware, USA Neurocrine Group Limited England and Wales Neurocrine UK Limited England and Wales Neurocrine Holdings Limited England and Wales Neurocrine Ireland Limited Ireland Neurocrine Therapeutics Limited Ireland Neurocrine Switzerland
February 10, 2025	EX-10.35	Amended and Restated Employment Agreement effective February 307632958 v9 Exhibit 10.35 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and Eiry W. Robe
February 10, 2025	EX-10.31	Amended and Restated Employment Agreement effective exhibit1031-kyleganoxame Exhibit 10.31 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and
February 10, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E
February 10, 2025	EX-10.33	Amended and Restated Employment Agreement effective February exhibit1033-ericbenevich Exhibit 10.33 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and
February 10, 2025	EX-10.4	Collaboration and License Agreement dated January 28, 2019 between Voyager Therapeutics, Inc. and the Company Exhibit 10.4 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NEUROCRINE BIOSCIENCES, INC. i TABLE OF CONTENTS ARTICLE 1 DEFINITIONS ......
February 10, 2025	EX-10.30	Amended and Restated Employment Agreement effective October 11, 2024 between the Company and Kyle W. Gano, Ph.D. exhibit1030-kyleganoxemp Exhibit 10.30 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective October 11, 2024 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and
February 10, 2025	EX-10.26	Neurocrine Biosciences, Inc. exhibit1026-executivesev Exhibit 10.26 1 NEUROCRINE BIOSCIENCES, INC. EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (Effective Date: February 7, 2025) 1. Introduction. The Neurocrine Biosciences, Inc. Executive Severance Plan (the “Plan”) is hereby established by the Compensation Committee (as defined below), effective upon the Effective Date written above. The purpose of the Plan is to pr
February 10, 2025	EX-10.34	Amended and Restated Employment Agreement effective Februar exhibit1034-judeonyiaxam Exhibit 10.34 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and
February 10, 2025	EX-10.32	Amended and Restated Employment Agreement effective February Exhibit 10.32 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (hereinafter this “Agreement”) is entered into effective February 7, 2025 (hereinafter the “Effective Date”) by and between NEUROCRINE BIOSCIENCES, INC., 6027 Edgewood Bend Court, San Diego, California 92130 (hereinafter the “Company”, as further defined in Annex I), and Matthew Abernethy (herein
February 10, 2025	EX-19.1	Neurocrine Biosciences, Inc. Insider Trading Policy exhibit191insidertrading Exhibit 19.1 NEUROCRINE BIOSCIENCES, INC. INSIDER TRADING POLICY INTRODUCTION During the course of your relationship with Neurocrine Biosciences, Inc. (the “Company”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the Company or another publicly-traded company with which the Company has business dealings. M
February 6, 2025	EX-99.1	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion
February 6, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N
January 27, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
January 27, 2025	EX-99.1	Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) - Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japa Exhibit 99.1 Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) - Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator - Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO, Jan. 27, 2025 – N
December 20, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
December 20, 2024	EX-99.1	Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia Exhibit 99.1 Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia • CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. • CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively thr
November 1, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
October 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCR
October 30, 2024	EX-3.2	Bylaws, as amended BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) Exhibit 3.2 BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page - i - ARTICLE I CORPORATE OFFICES .................................................................................. 1 1.1 REGISTERED OFFICE ................................................................................................
October 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N
October 30, 2024	EX-10.2	Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended 307473618 v2 NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 16, 2020 APPROVED BY THE STOCKHOLDERS: MAY 19, 2020 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 24, 2023 APPROVED BY THE STOCKHOLDERS: MAY 17, 2023 AMENDED AND RE
October 30, 2024	EX-10.3	Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2011 Equity Incentive 307480254 v2 Exhibit 10.3 NEUROCRINE BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2011 EQUITY INCENTIVE PLAN) NEUROCRINE BIOSCIENCES, INC. (the “Company”), pursuant to its 2011 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set fo
October 30, 2024	EX-99.1	Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance INGREZZA® (valbenazine) Third Quarter Net Product Sales of $613 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.30 - $2.32 Billion Board Authorizes $300 Million Share Repurchase Plan SAN DIEGO, October 30, 2024
October 30, 2024	EX-10.1	Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan, as amended 110132325 v9 1. NEUROCRINE BIOSCIENCES, INC. 2011 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 21, 2011 APPROVED BY THE STOCKHOLDERS: MAY 25, 2011 AMENDED BY THE STOCKHOLDERS: MAY 23, 2013 AMENDED BY THE STOCKHOLDERS: MAY 22, 2014 AMENDED BY THE STOCKHOLDERS: MAY 28, 2015 AMENDED BY THE STOCKHOLDERS: MAY 20, 2016 AMENDED BY THE STOCKHOLDERS: MAY 22, 2017 AMENDED BY THE STOCKHO
October 17, 2024	SC 13G	NBIX / Neurocrine Biosciences, Inc. / STATE STREET CORP Passive Investment SC 13G 1 NeurocrineBiosciencesInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEUROCRINE BIOSCIENCES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 64125C109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the
October 11, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
August 28, 2024	EX-99.2	Topline Results for Phase 2 Trial of NBI-1117568 (NBI-’568) in Schizophrenia August 28, 2024 Exhibit 99.2 2 Forward Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of ris nbix2024828-exhibit992 Topline Results for Phase 2 Trial of NBI-1117568 (NBI-’568) in Schizophrenia August 28, 2024 Exhibit 99.
August 28, 2024	EX-99.1	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia Exhibit 99.1 Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia •The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from Baseline •The Once-Daily 20 mg Dose
August 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 NEUROCRINE BIOSCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
August 1, 2024	EX-10.2	, between the Company and Voyager Therapeutics, Inc. Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is effective as of Ap
August 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B
August 1, 2024	EX-10.1	Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 16, 2020 APPROVED BY THE STOCKHOLDERS: MAY 19, 2020 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 24, 2023 APPROVED BY THE STOCKHOLDERS: MAY 17, 2023 AMENDED AND RESTATED BY THE
August 1, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 Neurocrine Biosciences, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $0.001 par value per share, 2020 Equity Incentive Plan O
August 1, 2024	EX-99.1	Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-’568 and Luvadaxistat Remain On Track in
August 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Num
August 1, 2024	S-8	As filed with the Securities and Exchange Commission on August 1, 2024 As filed with the Securities and Exchange Commission on August 1, 2024 Registration No.
May 28, 2024	EX-3.1	Certificate of Amendment of Bylaws Exhibit 3.1 BYLAW AMENDMENT 3.2 NUMBER OF DIRECTORS The board of directors shall consist of eleven (11) members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. The directors shall be divided into three classes, with the term of office of the firs
May 28, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Numbe
May 23, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
May 1, 2024	EX-99.1	Neurocrine Biosciences Reports First Quarter 2024 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2024 Financial Results INGREZZA® (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over-Year Growth INGREZZA® SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Da
May 1, 2024	EX-10.1	Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for grants on or after February 13, 2024 made under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Exhibit 10.1 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan RSU Award Grant Notice Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) a restricted stock unit award for the number of restricted stock units (“RSUs”) set forth below (the “RSU Award”) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the “Plan”). The RSU Award is subject to all of
May 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number
May 1, 2024	EX-10.2	Form of Stock Option Grant Notice and Option Agreement for grants made to Kevin Gorman on or after February 13, 2024 made under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Exhibit 10.2 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice Neurocrine Biosciences, Inc. (the “Company”) has granted to you (“Participant”) an option to purchase the number of shares of Common Stock set forth below (the “Option”) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the “Plan”). The Option is subject to all of the terms and conditions set
May 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE
April 10, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 10, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 10, 2024	ARS	ARS Annual Report 2023Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline with multiple mid-to-late- stage programs focused on diseases and disorders across neurology, neuroendocrinology, and neuropsychiatry.
February 13, 2024	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01535-neurocrinebioscience.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Neurocrine Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box
February 9, 2024	EX-97	Neurocrine Biosciences Exhibit 97 Neurocrine Biosciences, Inc. Incentive Compensation Recoupment Policy October 2023 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation
February 9, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E
February 9, 2024	EX-21.1	Subsidiaries of the Company Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine International, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland Neurocrine UK Limited England and Wales Neurocrine Switzerland GmbH Switzerland Diurnal Group Limited England and Wales Diurnal Limited England and Wales Di
February 7, 2024	EX-99.1	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion, Representing Year-over-Year Growth of 25% and 29% Respectively INGREZZA® (valbenazine) Full Year 2024 Net Product Sales Guidance of $2.1 - $2.2 Billion
February 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N
January 23, 2024	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us64125c1099012324.txt us64125c1099012324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) NEUROCRINE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64125C109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the approp
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 NEUROCRINE BIOS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
November 9, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
October 31, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCR
October 31, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N
October 31, 2023	EX-99.1	Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance INGREZZA® (valbenazine) Third Quarter Net Product Sales of $486 Million Representing 29% Year-Over-Year Growth INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.82 - $1.84 Billion Crinecerfont Adult and Pediatric CAHtalystTM Studies Met Primary Endpoint and Ke
October 6, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
October 5, 2023	EX-99.1	Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints Exhibit 99.1 Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints •CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and Adolescents with Congenital Adr
October 5, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
September 12, 2023	EX-99.1	Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) CAHtalyst™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Bas Exhibit 99.1 Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) CAHtalyst™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline Daily Glucocorticoid Dose with Androgen Control Key Secondary Endpoint Achieved Statistically Significant Decrease in Androstenedio
September 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 NEUROCRINE BIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employ
August 1, 2023	EX-10.1	Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended and restated Exhibit 10.1 NEUROCRINE BIOSCIENCES, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE: MARCH 16, 2020 APPROVED BY THE STOCKHOLDERS: MAY 19, 2020 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: MARCH 14, 2022 APPROVED BY THE STOCKHOLDERS: MAY 18, 2022 AMENDED BY THE COMPENSATION COMMITTEE: MARCH 24, 2023 APPROVED BY THE STOCKHOLDERS: May 17, 2023 TERMINATION DATE: MARCH 15,
August 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B
August 1, 2023	S-8	As filed with the Securities and Exchange Commission on August 1, 2023 As filed with the Securities and Exchange Commission on August 1, 2023 Registration No.
August 1, 2023	EX-99.1	Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance INGREZZA® (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Raised to $1.77 - $1.82 Billion SAN DIEGO, Aug. 1, 2023 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today an
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Num
August 1, 2023	EX-3.2	Bylaws, as amended q2-2023xexhibit32 Exhibit 3.2 BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page - i - ARTICLE I CORPORATE OFFICES .................................................................................. 1 1.1 REGISTERED OFFICE ..............................................................................
August 1, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 Neurocrine Biosciences, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $0.001 par value per share, 2020 Equity Incentive Plan O
July 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 NEUROCRINE BIOSCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
July 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 NEUROCRINE BIOSCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
July 12, 2023	EX-3.1	Certificate of Amendment of Bylaws Exhibit 3.1 BYLAW AMENDMENT 3.2 NUMBER OF DIRECTORS The board of directors shall consist of ten (10) members. The number of directors may be changed by an amendment to this bylaw, duly adopted by the board of directors or by the stockholders, or by a duly adopted amendment to the certificate of incorporation. The directors shall be divided into three classes, with the term of office of the first c
May 19, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction of Incorporation) (Commission
May 3, 2023	EX-10.1	Employment Agreement dated October 28, 2014 between the Company and Darin Lippoldt q1-2023x10qxexhibit101 Exhibit 10.1 threatened breach of any such provisions by Executive, in addition to any other relief (including damage) available to the Company under this Agreement or under law. (b) Exclusive. Both parties agree that the remedy specified in Section 7.9(a) above is not exclusive of any other remedy for the breach by Executive of the tenns hereof. 7.10 Counterparts. This Agre
May 3, 2023	EX-10.2	Collaboration and License Agreement dated January 8, 2023 between Voyager Therapeutics, Inc. and the Company q1-2023x10qxexhibit102 Exhibit 10.2 EXECUTION COPY CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. 1 COLLABORATION AND LICENSE AGREEMENT by and between VOYAGER THERAPEUTICS, INC. AND NEUROCRINE BIOSCIENCES,
May 3, 2023	EX-10.3	Stock Purchase Agreement dated January 8, 2023 between Voyager Therapeutics, Inc. and the Company q1-2023x10qxexhibit103 Exhibit 10.3 EXECUTION VERSION ACTIVEUS 197300656v.12 STOCK PURCHASE AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 ACTIVEUS 197300656v.12 TABLE OF CONTENTS Page 1. Definitions............................................................................................................................1 1.1 Defin
May 3, 2023	EX-10.4	Amended and Restated Investor Agreement dated January 8, 2023 between Voyager Therapeutics, Inc. and the Company q1-2023x10qxexhibit104 Exhibit 10.4 EXECUTION VERSION ACTIVEUS 197306930v.16 AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 - i - ACTIVEUS 197306930v.16 TABLE OF CONTENTS 1. Definitions.......................................................................................................................
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 NEUROCRINE BIOSCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number
May 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE
May 3, 2023	EX-99.1	Neurocrine Biosciences Reports First Quarter 2023 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2023 Financial Results INGREZZA® (valbenazine) First Quarter Net Product Sales of $410 Million INGREZZA® (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67 - $1.77 Billion SAN DIEGO, May 3, 2023 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and p
May 2, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 5, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 5, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 NEUROCRINE BIOSCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer o
February 24, 2023	SC 13D/A	VYGR / Voyager Therapeutics Inc / Neurocrine Biosciences Inc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) Kevin C. Gorman, Ph.D. Chief Executive Officer Neurocrine Biosciences, Inc. 12780 El Camino Real San Die
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 NEUROCRINE BIOS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
February 24, 2023	EX-99.1	AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 EX-99.1 Exhibit 99.1 AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Restrictions on Beneficial Ownership 6 3. Restrictions on Dispositions 7 3.1 Lock-Up 7 3.2 Certain Tender Offers 7 3.3 Sale Limitations 7 3.4 Offering Lock-Up 8 3.5 Transactions for
February 10, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
February 10, 2023	EX-3.1	Amended and Restated Bylaws Exhibit 3.1 BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) BYLAWS OF NEUROCRINE BIOSCIENCES, INC. (a Delaware corporation) TABLE OF CONTENTS Page - i - ARTICLE I CORPORATE OFFICES .................................................................................. 1 1.1 REGISTERED OFFICE ................................................................................................
February 9, 2023	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / JANUS HENDERSON GROUP PLC - JHG PLC OWNS <5% Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 6* Name of Issuer: NEUROCRINE BIOSCIENCES, INC. Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: 12/31/2022 Check the appropriate box to designate the rule pursuant to which this Schedu
February 9, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E
February 9, 2023	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01504-neurocrinebioscience.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Neurocrine Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo
February 9, 2023	EX-21.1	Subsidiaries of the Company Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland Neurocrine UK Limited England and Wales Diurnal Group Limited England and Wales Diurnal Limited England and Wales Diurnal Europe B.V. The Netherlands
February 6, 2023	EX-99.1	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $399 Million INGREZZA® (valbenazine) 2023 Net Product Sales Guidance of $1.67 - $1.77 Billion Enrollment Complete in Adult and Pediatric Registrational Studies of Crinecerfont for the Treatment of Conge
February 6, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N
January 23, 2023	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us64125c1099012323.txt us64125c1099012323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) NEUROCRINE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64125C109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the approp
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 NEUROCRINE BIOSCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
January 9, 2023	EX-99.1	Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases - Voyager to receive up-front considerati Exhibit 99.1 Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases - Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potentia
November 1, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCR
November 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File N
November 1, 2022	EX-99.1	Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance INGREZZA? (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA? (valbenazine) 2022 Net Product Sales Guidance Raised to $1.4 - $1.425 Billion Supplemental New Drug Application (sNDA) of Valbenazine For the Treatment of Chorea in Patients with Huntington Disease
August 30, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
August 4, 2022	EX-99.1	Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance Exhibit 99.1 Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance INGREZZA? (valbenazine) Second Quarter Net Product Sales of $350 Million INGREZZA? (valbenazine) 2022 Net Product Sales Guidance Raised to $1.35 - $1.40 Billion Essential Tremor Signal-Seeking Study Did Not Meet Specified Endpoints SAN DIEGO, Aug. 4, 2022 - Neurocrine Bioscienc
August 4, 2022	EX-10.3	Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, as amended and restated Exhibit 10.3 Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan Adopted by the Board of Directors: February 6, 2018 Approved by the Stockholders: May 24, 2018 Amended and Restated by the Compensation Committee: March 14, 2022 Approved by the Stockholders: May 18, 2022 1.General; Purpose. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Rela
August 4, 2022	EX-10.2	Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, as amended Exhibit 10.2 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Adopted by the Compensation Committee: March 16, 2020 Approved by the Stockholders: May 19, 2020 Amended and Restated by the Compensation Committee: March 14, 2022 Approved by the Stockholders: May 18, 2022 Termination Date: March 15, 2030 Table of Contents Page 1. General. 1 2. Shares Subject to the Plan. 1 3. Eligibility and Li
August 4, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 Neurocrine Biosciences, Inc. Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, $0.001 par value per share, 2020 Equity Incentive Plan O
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Num
August 4, 2022	S-8	As filed with the Securities and Exchange Commission on August 4, 2022 As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.
August 4, 2022	EX-10.1	Employment Agreement dated November 29, 2021 between the Company and Jude Onyia Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (hereinafter ?Agreement?) is entered into effective November 29, 2021 by and between Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (hereinafter the ?Company?), and Jude Onyia, Ph.D. (hereinafter ?Executive?). R E C I T A L S WHEREAS, the Company and Executive wish to set forth in this Agreement the terms
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE B
June 1, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
May 25, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
May 25, 2022	EX-99.1	Neurocrine Biosciences Announces Repurchase of Convertible Notes Exhibit 99.1 Neurocrine Biosciences Announces Repurchase of Convertible Notes SAN DIEGO, May 24, 2022 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) (the ?Company? or ?Neurocrine Biosciences?) today announced that it has entered into separate, privately negotiated transactions (the ?Agreements?) with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the ?2024 Notes?) to repur
May 23, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-22705 (Commission File Number
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE
May 4, 2022	EX-10.1	Commercial Lease dated February 8, 2022, by and between the Company and Gemdale Aperture Phase I, LLC COMMERCIAL LEASE By and Between Gemdale Aperture Phase I, LLC a Delaware limited liability company ?Landlord? and Neurocrine Biosciences, Inc.
May 4, 2022	EX-99.1	Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance INGREZZA? (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA? (valbenazine) 2022 Net Product Sales Guidance Reiterated at $1.25 - $1.35 Billion SAN DIEGO, May 4, 2022 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the f
April 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A 1 d332755ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi
April 7, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
February 14, 2022	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) NEUROCRINE BIOSCIENCES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 64125C109 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc
February 11, 2022	EX-4.3	First Supplemental Indenture, dated as of December 22, 2021, by and between the Company and U.S. Bank National Association, as Trustee Exhibit 4.3 NEUROCRINE BIOSCIENCES, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 20, 2021 2.25% Convertible Senior Notes due 2024 FIRST SUPPLEMENTAL INDENTURE, dated as of December 20, 2021 (this ?Supplemental Indenture?), among Neurocrine Biosciences, Inc., a Delaware corporation (the ?Company?), as issuer, and U.S. Bank National Associatio
February 11, 2022	EX-10.10	Collaboration and License Agreement dated November 22, 2021 between Heptares Therapeutics Limited and the Company Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT NEUROCRINE BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL Dated 22 November 2021 HEPTARES THERAPEUTICS LIMITED (1) AND NEUROCRINE BIOSCIENCES, INC. (2) COLLABORATION AND LICENSE AGREEMENT CONTENTS Clause Heading Page 1 DEFIN
February 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
February 11, 2022	EX-10.17	Form of Stock Option Grant Notice and Option Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan, and Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for use under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Exhibit 10.17 Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice Neurocrine Biosciences, Inc. (the ?Company?) has granted to you (?Participant?) an option to purchase the number of shares of Common Stock set forth below (the ?Option?) under the Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan (the ?Plan?). The Option is subject to all of the terms and conditions set
February 11, 2022	EX-99.1	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 Exhibit 99.1 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 INGREZZA? (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA? (valbenazine) 2022 Net Product Sales Guidance of $1.25 - $1.35 Billion Expanded Pipeline Expected to Deliver Multiple Registrational and Phase 2 Study Data Readouts
February 11, 2022	EX-21.1	Subsidiaries of the Company Exhibit 21.1 NEUROCRINE BIOSCIENCES INC. SUBSIDIARIES Name of Subsidiary Jurisdiction Neurocrine Continental, Inc. Delaware, USA Neurocrine Europe, Ltd. Ireland Neurocrine Therapeutics, Ltd. Ireland
February 11, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (E
February 10, 2022	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Neurocrine Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is
February 10, 2022	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / JANUS HENDERSON GROUP PLC - JANUS HENDERSON GROUP PLC OWNS >5% Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 5* Name of Issuer: NEUROCRINE BIOSCIENCES, INC. Title of Class of Securities: Common Stock CUSIP Number: 64125C109 Date of Event Which Requires Filing of this Statement: 12/31/2021 Check the appropriate box to designate the rule pursuant to which this Schedu
January 27, 2022	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / BlackRock Inc. Passive Investment us64125c1099012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) NEUROCRINE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64125C109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu
January 26, 2022	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / BlackRock Inc. Passive Investment us64125c1099012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) NEUROCRINE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 64125C109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu
January 18, 2022	CT ORDER	CT ORDER
January 6, 2022	EX-99.1	Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones Exhibit 99.1 Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones INGREZZA? (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $301 Million and 56,400 Total Prescriptions INGREZZA? (valbenazine) Preliminary Full-Year 2021 Net Product Sales of Approximately $1.1 Billion Supplemental New Drug Ap
January 6, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
December 30, 2021	CT ORDER	CT ORDER
December 23, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
November 22, 2021	EX-99.1	Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 Exhibit 99.1 Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 Sosei Heptares receive
November 22, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employe
November 15, 2021	LETTER	LETTER United States securities and exchange commission logo November 15, 2021 Matthew Abernethy Chief Financial Officer NEUROCRINE BIOSCIENCES INC 12780 El Camino Real San Diego, CA 92130 Re: NEUROCRINE BIOSCIENCES INC 10-K filed February 5, 2021 Form 8-K filed August 3, 2021 Form 8-K filed February 4.
November 3, 2021	CORRESP	*** November 3, 2021 Via EDGAR and FedEx Ms. Jeanne Baker Mr. Terence O'Brien United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Neurocrine Biosciences, Inc. Form 10-K filed February 5, 2021 Form 8-K filed August 3, 2021 Form 8-K filed February 4, 2021 File No. 000-22705 Ladies and Gentlemen: This letter is
November 1, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer
November 1, 2021	EX-99.1	Neurocrine Biosciences Reports Third Quarter 2021 Financial Results Exhibit 99.1 Neurocrine Biosciences Reports Third Quarter 2021 Financial Results INGREZZA? (valbenazine) Third Quarter 2021 Net Product Sales of $287 Million with Approximately 52,000 Total Prescriptions SAN DIEGO, Nov. 1, 2021 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021. ?Our third quarter results reflect INGRE
November 1, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRI
October 27, 2021	LETTER	LETTER United States securities and exchange commission logo October 27, 2021 Matthew Abernethy Chief Financial Officer NEUROCRINE BIOSCIENCES INC 12780 El Camino Real San Diego, CA 92130 Re: NEUROCRINE BIOSCIENCES INC 10-K filed February 5, 2021 Form 8-K filed August 3, 2021 Form 8-K filed February 4.
October 5, 2021	CORRESP	2 October 5, 2021 Via EDGAR and FedEx Ms. Jeanne Baker Mr. Terence O'Brien United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Neurocrine Biosciences, Inc. Form 10-K for the fiscal year ended December 31, 2020, filed February 5, 2021 Form 8-K filed August 3, 2021 Form 8-K filed February 4, 2021 File No. 00
September 22, 2021	LETTER	LETTER United States securities and exchange commission logo September 22, 2021 Matthew Abernethy Chief Financial Officer NEUROCRINE BIOSCIENCES INC 12780 El Camino Real San Diego, CA 92130 Re: NEUROCRINE BIOSCIENCES INC 10-K filed February 5, 2021 Form 8-K filed August 3, 2021 Form 8-K filed February 4.
August 10, 2021	SC 13G/A	NBIX / Neurocrine Biosciences, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 13 NEUROCRINE BIOSCIENCES INC COMMON STOCK Cusip #64125C109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #64125C109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 189,423 Item 6: 0 Item 7: 3,780,076 Item 8: 0 Item 9: 3,780,076 Item
August 3, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BI

DE:NB3	137,60 €
IT:1NBIX	135,45 €
GB:0K6R	157,92 $

NBIX / Neurocrine Biosciences, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings